Herpes simplex virus (HSV)-infected cells can activate the human complement system without interference of specific anti-HSV antibodies. Analysis by flow cytometry showed that C3-like molecules were deposited on the membrane of the infected cell when incubated with human serum without specific antibodies. Depletion of calcium to block the classical pathway of the complement system had no effect on fluorescence intensity. The complement activation could be blocked by chelating both calcium and magnesium or by heating the serum.
Several viruses, such as vesicular stomatitis virus (9) , infectious bovine rhinotracheitis vir-us (9), feline leukemia virus (17) , mumps virus (12) , measles virus (24) , Sendai virus (22) , influenza virus (18) , oncornaviruses (2), Epstein-Barr virus (19) , and respiratory syncytial virus (5, 13, 25) , activate the alternative complement pathway. Activation of complement by these viruses may result in lysis of the virus particle (2, 17) , neutralization (12) , lysis of virus-infected cells (4, 5) , or an indirect lytic event mediated by leukocytes through C3b and C3bi receptor binding (9, 13) .
Complement-mediated lysis of herpes simplex-virus (HSV)-infected cells loaded with specific antibodies can be a very effective killing mechanism (1, 4, 8, 11) . In a bovine system, Rouse et al. (23) found that complement could lead to enhancement of antibody-dependent cell-mediated cytotoxicity (ADCC). Bovine polymorphonuclear leukocytes (PMN) could also be cytotoxic in the presence of complement without the involvement of antibodies (i.e., complement-dependent cell-mediated cytotoxicity [CDCC]) (10) .
We studied the interaction between HSV type 1 (HSV-1) and HSV-2 and the human complement system without the involvement of antibodies. Cells infected with HSV activated the human complement system in the absence of antibodies, leading to the attachment of human PMN to the infected target cell.
MATERIALS AND METHODS
Chemicals. RPMI 1640, medium 199, and fetal calf serum (FCS) were obtained from GIBCO Laboratories (Paisley, Renfrewshire, United Kingdom); penicillin and streptomycin were obtained from Gist Brocades (Delft, The Netherlands). HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) was purchased from BDH for total (CH50) and alternative pathway (AP50) activity, and only those with normal complement levels were used (16) .
Isolation of human PMN. PMN were isolated and radiolabeled as described earlier (26 (27) , with slight modifications as reviewed recently by Emmet and Crowle (6) . Rabbit anti-human C3c, which cross-reacts with both C3 and C3b, was used to achieve precipitation in the second dimension. The percentage of conversion was determined by planimetry of the C3b peak area relative to the total C3-C3b area.
Complement activity. CH50 and AP50 activities were measured by a micromethod as described by Klerx et al. (16) 
RESULTS
Membrane deposition of complement factors. Infected cells were incubated with human serum containing high amounts of anti-HSV antibodies. Deposition of C3b on the membrane of the infected cell was quantified by fluorescence-activated cell-sorter (FACS) analysis of immunofluorescence after cells were incubated with FITC-labeled anti-C3 (which cross-reacts with C3b) (Fig. 1) . When this serum was heated for 30 min at 56°C before incubation or when incubation was performed in the presence of EDTA (10 mM) to remove complement activity, no fluorescence was observed.
Incubating these cells with serum without detectable amounts of anti-HSV antibodies but with intact human complement still resulted in fluorescence. EDTA treatment or heating of the negative serum also abolished fluorescence. When this incubation was performed in the presence of 10 mM Mg2' and 10 mM EGTA (ethylene glycol-bis(3-aminoethyl ether)-N,N,N',N',-tetraacetic acid; magnesium EGTA) to block only the classical route of complement activation, fluorescence was not diminished.
After infected cells were incubated with anti-HSV-positive serum and magnesium EGTA, fluorescence could still be demonstrated at levels comparable with that seen after incubation with serum without specific antibodies. Results were comparable for cells infected with either HSV-1 or HSV-2. No fluorescence was observed on mock-infected cells or infected cells incubated with medium and FITClabeled anti-C3 alone.
Conversion of fluid-phase C3. CH50 and AP50 levels of sera incubated with infected cells were only decreased when specific antibodies were present in the serum. In the absence J. VIROL. We used crossed immunoelectrophoresis as a more sensitive assay for complement activation. Sera were incubated with HSV-1-or 2-infected cells, and conversion of C3 to C3b was measured by crossed immunoelectrophoresis. Figure 2 shows that after incubation of serum with specific antibodies with HSV-infected cells, 58 ± 6% (HSV-1) or 59 ± 6% (HSV-2) of C3 is converted into C3b, compared with 45 ± 5% (HSV-1) or 46 ± 7% (HSV-2) when infected cells were incubated in serum without specific antibodies. When sera were incubated with mock-infected cells, no conversion was observed (i.e., the level equaled the level of normal human serum incubated at 37°C for 1 h without cells).
Lysis of infected cells. Complement-mediated lysis was measured in a chromium release assay. When specific anti-HSV antibodies were used in combination with human complement, lysis of HSV-infected cells occurred rapidly (:s80% within 15 min). But when no specific anti-HSV antibodies were present, lysis was never observed. Uninfected fibroblasts were not lysed at all.
As in the attachment assay, PMN were added to this test system. No significant enhancement of cytolysis could be demonstrated within short-time experiments (c2 h) even in the presence of specific antibodies. In longer assays (18 h), ADCC occurred in the absence of complement. Otherwise, lysis was already accomplished by the complement itself. In the absence of antibodies, no CDCC could be observed, even in 18-h assays (data not shown).
Attachment of PMN. Attachment of granulocytes to fibroblasts monolayers infected with HSV by specific anti-HSV antibodies could be enhanced when complement was present (Fig. 3) . When serum without detectable amounts of antibodies but with an intact complement system was used, PMN attachment to infected monolayers was 24.7 ± 2.7% compared with 8.2 ± 1.1% attachment to mock-infected monolayers. Adsorbed negative sera gave the same results as untreated negative sera. Preincubating negative serum with anti-C3 resulted in a decrease of attachment to background levels. DISCUSSION Cells infected with HSV-1 and HSV-2 can directly activate the human complement system and thereby mediate the attachment of human granulocytes. Deposition of complement factors on the membrane of cells infected with HSV was observed. When the serum was heated prior to incubation or when uninfected cells were used, no such effect was found. Complement activation could also occur in the absence of antibodies and independent of the classical pathway of complement because depletion of Ca2+ ions (by treatment with magnesium EGTA) still led to the deposition of a C3-like factor on the cell membrane, as determined by FACS analysis. Because FITC-conjugated anti-C3 was used, it was not possible to exactly determine which C3-like molecule was deposited on the plasma membrane. But crossed immunoelectrophoresis ( Fig. 1) showed conversion from C3 to C3b, at least in the fluid phase. Also, the fact that PMN attach to infected monolayers preincubated with negative serum suggests that it is C3b and/or C3bi which is deposited on the cell surface because PMN have receptors for these molecules (15, 20) .
The fact that mock-infected cells do not activate the complement pathway indicates that virus infection changes the cell membrane and causes it to activate complement. Considering the other immunological events that can counter HSV infection, such as ADCC, antibody-dependent complement lysis, and killer cell and cytotoxic lymphocyte cytotoxicity, we suggest that HSV-specified glycoproteins play an important role in this phenomenon (14, 21) .
The fact that HSV-1 glycoprotein C acts as a C3b receptor (7) could influence the results in immunofluorescence assays using anti-C3. However, by using HSV-2, which does not induce such a structure (29) , we demonstrated that it is not solely C3b binding that we measured but real complement activation. Also the fact that PMN can adhere to this structure indicates that it is not already bound by a C3b receptor but rather is attached to the membrane of the infected cell by its amino-terminal site.
Although serum with specific anti-HSV antibodies induces complement-mediated cell lysis within 15 min and although infected fibroblasts appeared to be able to activate the complement system via an antibody-independent pathway, we were not able to demonstrate cell lysis in the absence of antibodies. Also, no complement consumption could be measured by CH50 or AP50 assay. This indicates that only (9, 24) .
Although PMN adhere to infected fibroblasts in the presence of complement, no antibody-independent, PMN-mediated lysis occurred. This is analogous to the binding of bacteria in the absence of antibodies and the lack of triggering the PMN thereafter (28) . These observations in an in vitro model, totally composed of human components, indicate that HSV-1 and HSV-2 are activators of an antibodyindependent complement route. PMN can adhere to infected cells in combination with intact complement without the need for specific antibodies. In vivo, this may play a role in countering HSV infections with special emphasis on primary infections when antibodies and specific T cells are not yet present. The interaction of this phenomenon with other host defense mechanisms warrants further investigation.
